Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

10.1007/s00280-006-0270-1

Saved in:
Bibliographic Details
Main Authors: Yeo, W., Zee, B., Ma, B., Lam, K.C., Mo, F.K.F., Ng, E.K.W., Ho, R., Chan, A.T.C., Boyer, M., Clarke, S., Beale, P., Chung, H.C., Roh, J.K., Rha, S.Y., Jeung, H.C., Ong, S.Y.K., Lim, R., Soo, R., Goh, B.C.
Other Authors: PHARMACOLOGY
Format: Article
Published: 2011
Subjects:
First line chemotherapy
Irofulven
Stomach cancer
Online Access:http://scholarbank.nus.edu.sg/handle/10635/27257
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore

Internet

http://scholarbank.nus.edu.sg/handle/10635/27257

Similar Items